Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman reiterated a Speculative Buy rating on Intensity Therapeutics (NASDAQ:INTS) and maintained a $12 price target.
March 21, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intensity Therapeutics maintains a Speculative Buy rating and a $12 price target from Benchmark analyst Robert Wasserman.
The reiteration of a Speculative Buy rating and maintenance of a $12 price target by a Benchmark analyst could positively influence investor sentiment towards INTS, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100